Other
Jin LI
Total Trials
2
Recruiting
0
Active
0
Completed
0
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
Failure Rate
0.0%
0 terminated/withdrawn out of 2 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed trials have results
Key Signals
Enrollment Performance
Analytics
N/A
1(50.0%)
Phase 2
1(50.0%)
2Total
N/A(1)
Phase 2(1)
Activity Timeline
Global Presence
Loading network data...
Clinical Trials (2)
Showing 2 of 2 trials
NCT07466901Not ApplicableNot Yet Recruiting
A Single-arm, Multicenter, Phase II Clinical Study of Camrelizumab Combined With Famitinib in Adjuvant Therapy After Radical Resection of Cervical Cancer
Role: lead
NCT06081595Phase 2Not Yet Recruiting
Fluzoparib Combined With Apatinib in Relapsed Ovarian Carcinoma Maintenance Treatment
Role: lead
All 2 trials loaded